Anthem Biosciences FY26 PAT rises 31% to Rs 592 crore
Anthem Biosciences reported a 31% increase in profit after tax for FY26, reaching Rs. 592 crores, driven by an 18% rise in total revenue to Rs. 2,280 crores. The fourth quarter emerged as the highest revenue quarter, with consolidated sales of Rs. 611 crores. The company announced a significant capex plan of Rs. 1,200 crores for the Phase 1 expansion of Unit 4 to enhance custom synthesis and fermentation capacities over the next two years.
*this image is generated using AI for illustrative purposes only.
Anthem Biosciences has reported its financial results for the quarter and year ended March 31, 2026, accompanied by the release of its earnings conference call transcript. The company concluded the fiscal year with a strong performance, posting a profit after tax (PAT) of Rs. 592 crores, a growth of 31% over the previous year. Net profit margins stood at 26% for the full year.
Financial Performance
For the full year FY26, the company achieved a total revenue of Rs. 2,280 crores, an 18% increase compared to the prior year. Consolidated revenue from operations reached Rs. 2,124 crores. The CRDMO business was the primary contributor, generating Rs. 1,773 crores, which represents 83% of the total revenue and reflects an 18% growth. Specialty ingredients contributed Rs. 352 crores.
The fourth quarter of FY26 marked the highest revenue quarter in the company's history. Consolidated revenues for Q4 reached Rs. 611 crores, a year-on-year increase of 26%. The CRDMO segment delivered Rs. 513 crores in revenue for the quarter, growing by 31%, while specialty ingredients recorded Rs. 98 crores. Quarterly PAT stood at Rs. 190 crores, a surge of 130% on a YoY basis with margins of 28.7%.
| Metric | FY26 Value | YoY Growth |
|---|---|---|
| Total Revenue | Rs. 2,280 crores | 18% |
| Revenue from Operations | Rs. 2,124 crores | - |
| PAT | Rs. 592 crores | 31% |
| EBITDA | Rs. 990 crores | 31% |
| Net Cash Position | Rs. 1,375 crores | - |
Operational Highlights and Outlook
Management highlighted that the impact of destocking is largely behind the company, with expectations of restocking driving future growth. The company's EBITDA for the year was Rs. 990 crores, with margins expanding to 43.4%. Looking ahead, the company outlined significant capital expenditure plans focused on expanding its manufacturing capabilities.
The board has approved a major expansion plan for Unit 4, which will be the company's largest project to date. The company plans to invest approximately Rs. 1,200 crores across FY27 and FY28 for Phase 1 of this expansion. This phase is expected to add 365 kiloliters of custom synthesis capacity and 100 kiloliters of fermentation capacity. The capex for the upcoming year is anticipated to be around Rs. 700 crores. Management stated that capacity additions in Unit 2 and Unit 3 provide sufficient headroom until Unit 4 becomes operational.
How will the Rs. 1,200 crore Unit 4 expansion impact Anthem Biosciences' competitive positioning in the global CRDMO market once operational in FY28-29?
With destocking headwinds largely resolved, which therapeutic segments or geographies are most likely to drive the anticipated restocking-led revenue acceleration in FY27?
Given Anthem's strong net cash position of Rs. 1,375 crores alongside heavy capex commitments, could the company pursue strategic acquisitions or partnerships to accelerate its CRDMO pipeline?
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
